Results 81 to 90 of about 17,823 (170)

Generation of the Camptothecin Scaffold by a Flavin‐Catalyzed Photooxidative Skeletal Reorganization

Angewandte Chemie, Volume 138, Issue 36, 1 September 2026.
The biosynthetic pathway of the anticancer drug precursor camptothecin involves an enigmatic skeletal reorganization from a 6/5/6 tetrahydro‐β‐carboline to a 6/6/5 pyrroloquinoline ring system. Here, we show that this transformation can be achieved by photooxidation with flavin cofactors, such as flavin mononucleotide (FMN) as catalysts.
Shenyu Liu, Zeliang Zhang, Benedikt Seligmann, Van Hung Bui, Tuan‐Anh Minh Nguyen, Thu‐Thuy T. Dang, Jakob Franke   +6 more
wiley   +1 more source

Pharmacokinetic Comparison of Three Different Administration Routes for Topotecan Hydrochloride in Rats

Pharmaceuticals, 2020
Topotecan is actively used in clinic, with its primary use being in treatment of various types of cancer. The approved administration routes are oral and intravenous.
Seung-Hyun Jeong, Ji-Hun Jang, Yong-Bok Lee   +2 more
doaj   +1 more source

Intrathecal topotecan in adult patients with neoplastic meningitis

, 2010
PURPOSE: The efficacy and safety of intrathecal topotecan were assessed in patients with neoplastic meningitis (NM) by retrospective chart review. SUMMARY: Fourteen patients (median age, 57 years) with NM were treated with the standard of care (i.e ...
Gammon, David C., Bhatt, Mansi S., Van Horn, Alexis, Benvenuti, Matthew, Tran, Lan, Glantz, Michael J.   +5 more
core   +1 more source

Topotecan and Ginkgolic Acid Inhibit the Expression and Transport Activity of Human Organic Anion Transporter 3 by Suppressing SUMOylation of the Transporter

Pharmaceutics
Organic anion transporter 3 (OAT3), expressed at the basolateral membrane of kidney proximal tubule cells, facilitates the elimination of numerous metabolites, environmental toxins, and clinically important drugs.
Zhou Yu, Guofeng You
doaj   +1 more source

Topotecan uptake and efflux in topotecan resistant cancer cells

, 2000
喜樹鹼能抑制第一型拓蹼異構酵素，在實驗室中可抑制癌細胞生長。Topotecan及CPT-11 是兩個喜樹鹼的衍生物，最近已 開發成功。Topotecan 可治療卵巢癌而CPT-11 可治療大腸癌。目前二者都使用在各種癌症的臨床試驗，以尋求更廣泛的適 應症。以喜樹鹼置於癌細胞生長培養液中，往往產生對所有喜樹鹼衍生物的抗藥性。進一步分析可發現，抗藥性癌細胞中，第一型拓蹼異構酵素可能會下降或是產生突變，以致對喜樹鹼抑制劑的敏感度下降。我們先前發現，以第二型拓蹼異構酵素抑制劑mitoxantrone ...
楊志新
core  

Assessment of Anti-Cytogenotoxic Effects of Quercetin in Animals Treated with Topotecan [PDF]

, 2011
The present investigation was directed to study the possible chemoprotective activity of orally administered quercetin against topotecan-induced cyto- and genotoxicity towards mouse somatic cellsin vivo.
Saleh A. Bakheet
core   +1 more source

Novobiocin Sensitizes Bcrp/Mxr/Abcp Overexpressing Topotecan-Resistant Human Breast Carcinoma Cells to Topotecan and Mitoxantrone

, 2009
Background : Novobiocin was shown to sensitize cancer cells to etoposide and alkylating agents. Human breast carcinoma cells exposed to topotecan ( MCF7/TPT-300 cells) developed resistance to both mitoxantrone and topotecan.
YANG, CHIH-HSIN;CHEN, YAO-CHANG;KUO, MIN-LIANG, 楊志新;陳耀昌;郭明良   +1 more
core  

Development and Validation of an HPLC Method for Analysis of Topotecan in Human Cerebrospinal Fluid and Its Application in Elimination Evaluation of Topotecan after Intraventricular Injection

, 2021
Intrathecal administration of anticancer drugs is an effective dosage strategy, but the elimination of intraventricular drugs is not uniform in all patients.
Mariko Kinoshita, Naoki Yoshikawa, Ryuji Ikeda, Hiroshi Moritake, Tsubasa Yokota, Ai Yamada, Yusei Yamada   +6 more
core   +1 more source

Phase I dose escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancer

BMC Cancer, 2007
Background A platinum doublet is the current standard treatment for good performance status patients with advanced non-small cell lung cancer (NSCLC) and extensive stage small cell lung cancer (SCLC) with good performance status.
Kraft Andrew S, Meyer Mario L, Chaudhary Uzair, Garrett-Mayer Elizabeth, Green Mark R, Sherman Carol A, Beldner Matthew A, Montero Alberto J   +7 more
doaj   +1 more source

No evidence that amifostine influences the plasma pharmacokinetics of topotecan in ovarian cancer patients

, 2002
Objective: This aim of this study was to compare the pharmacokinetics of topotecan in the presence and absence of preceding amifostine to reduce the risk of side effects in patients with advanced ovarian cancer.
Zackrisson, Anna-Lena, Malmström, Henric,, Peterson, Curt   +2 more
core   +1 more source